psychedelics investing Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
psychedelics investing Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
psychedelics investing Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
psychedelics investing Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
psychedelics investing Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
psychedelics investing Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
psychedelics investing Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
psychedelics investing Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
psychedelics investing Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
psychedelics investing Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
psychedelics investing Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
psychedelics investing Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
psychedelics investing Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Spartan Metals Receives BLM Approval for Seven Additional Drill Sites at its Tungstonia Claims, Nevada
